Summary
In this study we report a randomized double-blind, placebo-controlled trial to evaluate the effect of ORG 2766 in IDDM patients with peripheral neuropathy. Sixty-two patients were selected based on the following criteria: abnormal vibration perception threshold above the 95th-percentile adjusted for age and/or abnormal warm temperature threshold, both measured in the right hand. The patients were randomized into two treatment groups after baseline studies: Group 1 was treated with placebo and Group 2 was treated with 3 mg of the ACTH4–9 analogue ORG 2766 every 24 h. The total study period was 1 year. After 1 year of treatment there was a significant improvement in vibration threshold in Group 1 compared to Group 2. No other parameters improved in the study period. The number of patients selected may have been too small to detect a more important treatment effect. We conclude from this study that ORG 2766 can improve vibration threshold, indicating large myelinated fibre function, but does not affect any the other neurophysiological function tests.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- IDDM:
-
Insulin-dependent diabetes mellitus
- NIDDM:
-
non-insulin-dependent diabetes mellitus
- ACTH:
-
adrenocorticotropic hormone
- SNCV:
-
sensory nerve conduction velocity
- MNCV:
-
motor nerve conduction velocity
References
Dyck PJ, James J, O'Brien PC (1987) Diagnosis, staging and classification of diabetic neuropathy and association with other complications. In: Dyck PJ, Thomas PK, Asbury AK, Winegrad AI, Porte D (eds) Diabetic neuropathy. Saunders, Philadelphia, pp 36–44
Pirart J (1987) Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care 1: 168–188
Brown MJ, Asbury AK (1984) Diabetic neuropathy. Ann Neurol 15: 2–12
Dyck PJ (1988) Detection, characterisation and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 11: 21–32
Harati Y (1987) Diabetic peripheral neuropathies. Ann Int Med 107: 546–559
Finegold D, Lattimer SA, Nolle S, Bernstein M, Greene DA (1983) Polyol pathway activity and myo-inositol metabolism: a suggested relationship in pathogenesis of diabetic neuropathy. Diabetes 32: 988–992
Dyck PJ, Sherman WR, Hallcher LM et al. (1980) Human diabetic endoneurial sorbitol, fructose and myo-inositol related to the sural nerve morphometry. Ann Neurol 8: 590–596
Greene DA, DeJesus PV Jr, Winegrad AI (1975) Effects of insulin and dietary myo-inositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J Clin Invest 55: 1326–1336
Greene DA, Lattimer SA (1982) Sodium-and energy dependent-uptake of myoinositol by rabbit peripheral nerve: competitive inhibition by glucose and lack of insulin. J Clin Invest 70: 1009–1018
Greene DA, Lewis RA, Lattimer SA, Browne MG (1983) Selective effect of myo-inositol administration on sciatic and tibial motor nerve conduction velocity parameters in streptozotocin-diabetic rat. Diabetes 31: 573–578
Low PA, Tuck RR, Dyck PJ, Schmelzer JD, Yao JK (1984) Prevention of some electrophysiologic and biochemical abnormalities with oxygen supplementation in experimental diabetic neuropathy. Proc Natl Acad Sci USA 81: 6894–6898
Low PA, Schmelzer JD, Ward KK, Yao JK (1986) Experimental chronic hypoxic neuropathy: relevance to diabetic neuropathy. Am J Physiol 250:E94-E99
Low PA (1987) Recent advances in the pathogenesis of diabetic neuropathy. Muscle Nerve 10: 121–128
Vlassara H, Brownlee M, Cerami A (1983) Excessive non enzymatic glycosylation of peripheral and central nervous system myelin components in diabetic rats. Diabetes 32: 670–674
Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end-products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315–1321
Martyn CN, Reid W, Young RJ, Ewing DJ, Clarke BF (1987) Six-month treatment with sorbinil in asymptomatic diabetic neuropathy; failure to improve abnormal nerve function. Diabetes 36: 987–990
O'Hare JP, Morgan MH, Alden P, Chissel S, O'Brien IAD, Corral RJM (1988) Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil. Diabetic Med 5: 537–542
Guy RJC, Gilbey SG, Sheehy M, Asselman P, Watkins PJ (1988) Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment. Diabetologia 31: 214–220
Florkowski CM, Rowe BR, Nightingale S, Harvey TC, Barnett AH (1991) Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy. Diabetes 40: 129–133
Judzewitsch RG, Jaspan JB, Polonsky KS et al. (1983) Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. New Engl J Med 308: 119–125
Boulton AJM, Lenin S, Comstock J (1990) A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic neuropathy. Diabetologia 33: 431–437
Gorio A, Aporli F, Di Gregorio F, Schiavinato A, Siliprandi R, Viladello M (1984) Ganglioside treatment of genetic and alloxan-induced diabetic rats. In: Ledeen RW, Yu RK, Rapport MM, Suzuki K (eds) Advances in experimental medicine and biology, vol. 174. Plenum Press, New York, pp 549–564
Lingetti M, Cerqua R, Corgliano G et al. (1991) Gangliosides for the treatment of diabetic neuropathy; A dose-finding study (abstract). Diabetes 40: 384
de Koning P, Gispen WH (1987) Org 2766 improves functional and electrophysiological aspects of regenerating sciatic nerve in the rat. Peptides 8: 415–422
Gerritsen van der Hoop R, de Koning P, Neijt JP, Jennekens FGI, Gispen WH (1988) Efficacy of the neuropeptide ORG 2766 in the prevention and treatment of cis-platinin-induced neurotoxicity in rats. Eur J Cancer Clin Oncol 24: 637–642
Gerritsen van der Hoop R, Vecht CJ, van der Burg MEL et al. (1990) Prevention of cisplatin neurotoxicity with an ACTH(4–9) analogue in patients with ovarian cancer. N Engl J Med 322: 89–94
van de Zee CEEM, Gerritsen van der Hoop R, Gispen WH (1989) Beneficial effect of Org 2766 in treatment of peripheral neuropathy in streptozotocin-induced diabetic rats. Diabetes 38: 225–230
Bravenboer B, Kappelle AC, van Buren T, Erkelens DW, Gispen WH (1993) ACTH-analogue org 2766 can ameliorate existing neuropathy in diabetic rats. Acta Diabetologica 30: 21–24
Bravenboer B, Kappelle AC, van Buren T, Erkelens DW, Gispen WH (1992) ACTH4–9-analogue ORG 2766 improves existing neuropathy in the BB/Wor model (abstract). Diabetes 41: 139
Jamal GA, Hansen S, Weir AI, Ballantyne JP (1985) An improved automated method for the measurement of thermal thresholds.1.normal subjects. J Neurol Neurosurg Psychiatry 48: 354–360
Bravenboer B, van Dam PS, Hop J, van de Steenhoven J, Erkelens DW (1992) Thermal threshold testing for the assessment of small fibre dysfunction: normal values and reproducibility. Diabetic Med 9: 546–549
Ewing DJ, Clarke BF (1982) Diagnosis and management of diabetic autonomic neuropathy. BMJ 285: 916–918
Imholz BPM, van Montfrans GA, Settels JJ, van der Hoeven GMA, Karemaker JM, Wieling W (1988) Continuous non-invasive blood pressure monitoring: reliability of Finapress device during the Valsalva manoevre. Cardiovasc Res 22: 390–397
Oh SJ (1984) Clinical electromyography: nerve conduction studies. University Park Press, Baltimore, pp 93–113
Troni W, Cantello R, Rainero I (1983) Conduction velocity along human muscle fibers in situ. Neurology 33: 1453–1459
Visser SL, Zonneveldt A, de Rijke W, Don JA, Martens EIF, Stam D (1983) Normal Hoffmann reflex latencies (HM interval) in relation to age and body length. Clin Neurol Neurosurg 85: 85–91
Lanting P, Bos JE, Aartsen J, Schuman L, Reichert-Thoen JWM, Heimans JJ (1990) Assessment of pupillary light reflex latency and darkness adapted pupil size in control subjects and in diabetic patients with and without cardiovascular autonomic neuropathy. J Neurol Neurosurg Psych 53: 912–914
Strand FL, Rose KJ, Zuccarelli LA et al. (1991) Neuropeptide hormones as neurotrophic factors. Physiol Rev 71: 1017–1046
Strand FL, Kung TT (1980) ACTH accelerates recovery of neuromuscular function following crushing of peripheral nerve. Peptides 1: 135–138
De Koning P, Gispen WH (1987) Org 2766 improves functional and electrophysiological aspects of regenerating sciatic nerve in the rat. Peptides 8: 415–422
De Koning P, Verhaagen J, Sloot W, Jennekens FGI, Gispen WH (1989) ORG 2766 stimulates collateral sprouting in rat soleus muscle following partial denervation. Muscle Nerve 12: 353–359
Van der Zee CEEM, Nielander HB, Vos JP et al. (1989) Expression of growth-associated protein B-50/GAP43 in dorsal root ganglia and sciatic nerve during regenerative sprouting. J Neurosci 9: 3505–3512
De Koning P, Brakkee JH, Gispen WH (1986) Methods for producing a reproducible crush in the sciatic and tibial nerve of the rat and rapid and precise testing of return of sensory function; beneficial effect of melanocortins. J Neurol Sci 74: 237–246
Young RJ, Martyn CN, Clarke BF, Ewing DJ (1991) Preliminary observations on the use of the aldose reductase inhibitor drug ponalrestat in diabetic neuropathy. Diabetes Nutr Metab 4: 287–292
The γ-Linolenic Acid Multicenter Trial Group (1993) Treatment of diabetic neuropathy with γ-linolenic acid. Diabetes Care 16: 8–15
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bravenboer, B., Hendrikse, P.H., Oey, P.L. et al. Randomized double-blind placebo-controlled trial to evaluate the effect of the ACTH4–9 analogue ORG 2766 in IDDM patients with neuropathy. Diabetologia 37, 408–413 (1994). https://doi.org/10.1007/BF00408479
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00408479